What is Grace Therapeutics, Inc.'s share price today?
Grace Therapeutics, Inc. (GRCE) share price today is $1.76 as of October 27, 2026 at 12:04 AM IST. The stock touched a day high of $2.02 and a day low of $1.69.What exchange does Grace Therapeutics, Inc. stock trade on, and under what ticker symbol?
Grace Therapeutics, Inc. stock trades on NASDAQ under the ticker symbol GRCE.What is Grace Therapeutics, Inc.'s market capitalization?
Grace Therapeutics, Inc.'s market capitalization is $40.59M as of October 27, 2026 at 12:04 AM IST.What is Grace Therapeutics, Inc.'s price-to-earnings (P/E) ratio?
Grace Therapeutics, Inc.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.What is Grace Therapeutics, Inc.'s price-to-book (P/B) ratio?
Grace Therapeutics, Inc.'s price-to-book (P/B) ratio is 0.65 as of October 26, 2026.Can Indian investors buy Grace Therapeutics, Inc. shares?
Yes, You can buy Grace Therapeutics, Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Grace Therapeutics, Inc. shares from India?
Indian investors can buy Grace Therapeutics, Inc. shares in three steps: 1. Search Grace Therapeutics, Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Grace Therapeutics, Inc. shares for Indian investors?
Since Grace Therapeutics, Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Grace Therapeutics, Inc. shares via Tickertape?
Indian investors can start investing in Grace Therapeutics, Inc. (GRCE) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 5.6625 shares at the current price of $1.76.
$
₹
$1.768.49% (-0.16)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
0.65
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-1.17
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 2 analysts reports
Buy2 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+208.65%
Earnings Growth
-19.22%
Rev. Growth
—
Company Profile
Company Profile
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$1.93Baseline
Analyst Target - 1 year
Target$5.96+208.65%
All values in $
2026
Current$1.93Baseline
Analyst Target - 1 year
Target$5.96+208.65%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2026
Current$-0.64Baseline
Forecast for Mar 2027
High$-0.76-19.22%
Average$-0.76-19.22%
Low$-0.76-19.22%
All values in $
2026
Current$-0.64Baseline
Forecast for Mar 2027
High$-0.76-19.22%
Average$-0.76-19.22%
Low$-0.76-19.22%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - |
| Net Income | -4.29 | -3.57 | -3.43 | -5.97 | 0.90 | -3.36 | -1.30 | -3.17 | -1.17 | -15.79 |
| Net Profit Margin | - | - | - | - | 11321.66% | - | - | - | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. | - | 0.65 | - |
| Eli Lilly and Company | 42.74 | 30.78 | 1.15 |
| Johnson & Johnson | 40.03 | 7.63 | 2.82 |
Price Comparison
Price Comparison
Compare GRCE with any stock or ETFCompare GRCE with any stock or ETF
Comparing from
GRCE
LLY
JNJ
The 12-month consensus target implies 208.65% growth, versus a trailing 3-year CAGR of -6.88%.